Survivin expression in tuberous sclerosis complex cells

Molecular Medicine

Volumn 13, Issue 3-4, 2007, Pages 166-177

  Carelli, Stephana ^a,b   Lesma, Elena ^a   Paratore, Simona ^a,b   Grande, Vera ^a   Zadra, Giorgia ^a   Bosari, Silvano ^a   Di Giulio, Anna Maria ^a   Gorio, Alfredo ^a,b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SURVIVIN; TUBERIN;

ADULT; ANGIOMYOLIPOMA; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CASE REPORT; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUBEROUS SCLEROSIS;

ADULT; ANGIOMYOLIPOMA; CELLS, CULTURED; FEEDBACK, BIOCHEMICAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; INSULIN-LIKE GROWTH FACTOR I; MUSCLE, SMOOTH; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 34250658843     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/2006-00091.Carelli     Document Type: Article

References (58)

1. O'Callaghan FJ, Shiell AW, Osborne JP, Martyn CN (1998) Prevalence of tuberous sclerosis estimated by capture-recapture analysis. Lancet 351:1490.
2. Young J, Povey S (1998) The genetic basis of tuberous sclerosis. Mol. Med. Today. 4:313-9.
3. Karbowniczek M, Yu J, Henske EP (2003) Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplastic and non-neoplastic vascular structures. Am. J. Pathol. 162:491-500.
4. Neumann HP, Schwarzkopf G, Henske EP (1998) Renal angiomyolipomas, cysts, and cancer in tuberous sclerosis complex. Semin. Pediatr. Neurol. 5:269-75.
5. Henske EP (2005) Tuberous sclerosis and the kidney: from mesenchyme to epithelium, and beyond. Pediatr. Nephrol. 20:854-7.
6. Henske EP (2003) Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosom. Cancer. 38:376-81.
7. Carsillo T, Astrinidis A, Henske EP (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. USA. 97:6085-90.
8. van Slegtenhorst M et al. (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7:1053-7.
9. Dabora SL et al. (2001) Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am. J. Hum. Genet. 68:64-80.
10. Tapon N, Ito N, Dickson BJ, Treisman JE, Hariharan IK (2001) The drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105:345-55.
11. Hengstschlager M et al. (2001) Tuberous sclerosis gene products in proliferation control. Mutat. Res. 488:233-9.
12. Edinger AL, Thompson CB (2002) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell. 13:2276-88.
13. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signaling. Nat. Cell. Biol. 4:648-57.
14. Dan HC et al. (2002) PI3K/AKT pathway regulates TSC tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277:35364-70.
15. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:151-62.
16. Deveraux QL, Reed JC (1999) IAP family proteins - suppressors of apoptosis. Genes Dev. 13:239-52.
17. Salvesen GS, Duckett CS (2002) IAP proteins: blocking the road to death's door. Nat. Rev. Mol. Cell. Biol. 3:401-10.
18. Verdecia MA et al. (2000) Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 7:602-8.
19. Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3:917-21.
20. Altieri DC (2004) Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm. J. Cell. Biochem. 92:656-63.
21. Li F, Ling X (2006) Survivin study: an update of "what is next wave"? J. Cell. Physiol. 208:476-86.
22. Li F et al. (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 396:580-4.
23. Chen J et al. (2000) Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia. 2:235-41.
24. Li F et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat. Cell. Biol. 1:461-6.
25. Olie RA et al. (2000) A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 60:2805-9.
26. Reed JC, Bischoff JR (2000) BIRinging chromosomes through cell division - and survivin' the experience. Cell. 102:545-8.
27. Grossman D et al. (2001). Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53. J. Clin. Invest. 108:991-9.
28. Grossman D, Kim PJ, Schechner JS, Altieri DC (2001). Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc. Natl. Acad. Sci. USA. 98:635-40.
29. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW (2001) Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J. Natl. Cancer Inst. 93:1541-52.
30. Yamamoto T, Manome Y, Nakamura M, Tanigawa N (2002) Downregulation of survivin expression by induction of the effector cell protease receptor-1 reduces tumor growth potential and results in an increased sensitivity to anticancer agents in human colon cancer. Eur. J. Cancer 38:2316-24.
31. Zhou M et al. (2002) DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J. Pharmacol. Exp. Ther. 303:124-31.
32. Beltrami E, Plescia J, Wilkinson JC, Duckett CS, Altieri DC (2004) Acute ablation of survivin uncovers p53-dependent mitotic checkpoint functions and control of mitochondrial apoptosis. J. Biol. Chem. 279:2077-84.
33. McNeish IA et al. (2005) Survivin interacts with Smac/DIABLO in ovarian carcinoma cells but is redundant in Smac-mediated apoptosis. Exp. Cell Res. 302:69-82.
34. O'Connor DS et al. (2000) Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. USA. 97:13103-7.
35. Marusawa H et al. (2003) HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2:2729-40.
36. Song Z, Yao X, Wu M (2003) Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J. Biol. Chem. 278:23130-40.
37. Adida C, et al. (1998) Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-3.
38. Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 7:542-7.
39. Tran J et al. (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 64:781-8.
40. O'Connor DS et al. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156:393-8.
41. Aoki Y, Feldman GM, Tosato G (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 101:1535-42.
42. Sommer KW et al. (2003) Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene. 22:4266-80.
43. Mirza A et al. (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21:2613-22.
44. Hoffman WH et al. (2002) Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277:3247-57.
45. Dan HC et al. (2004) Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene. 23:706-15.
46. Lesma E et al. (2005) Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: EGF is the required growth factor. Am. J. Path. 167:1093-103.
47. Xu ZX et al. (2004) Promyelocyte leukemia protein 4 induces apoptosis by inhibition of survivin expression. J. Biol. Chem. 279:1838-44.
48. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer. 3:46-54.
49. Bonetti F et al. (1994) Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma - the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology. 26:230-6.
50. Bjornsson J et al. (1996) Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am. J. Pathol. 149:1201-8
51. Hengartner MO. (2000) The biochemistry of apoptosis. Nature. 407:770-6.
52. Ambrosini G, Adida C, Sirugo G, Altieri DC (1998) Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J. Biol. Chem. 273:11177-82.
53. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC (2003) Survivin and molecular pathogenesis of colorectal cancer. Lancet. 362:205-9.
54. Asanuma H et al. (2005) Survivin expression is regulated by co-expression of human epidermal growth factor receptor 2 and epidermal growth factor via phosphatiylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 65:11018-25.
55. Ling X, Bernacki RJ, Brattain MG, Li F (2004) Induction of survivin expression by taxol (Paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J. Biol. Chem. 279:15196-203.
56. Zhang M, Latham DE, Delaney MA, Chakravarti A (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 24:2474-82.
57. Testa JR, Tsichilis PN (2005) AKT signaling in normal and malignant cells. Oncogene. 24:7391-3.
58. + cells and modulates cell cycle and proliferation of mouse hematopoietic progenitor cells. Blood 100:2463-71.